Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration
 Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 23, 2000, and December 5, 2000, Cerilliant Corporation, 14050 Summit Drive #121, P.O. Box 201088, Austin, Texas 78708-0189, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below: Drug
ScheduleCathinone (1235)
IMethcathinone (1237)
IN-Ethylamphetamine (1475)
IN,N-Dimethylamphetamine (1480)
IAminorex (1585)
I4-Methylaminorex (cis isomer) (1590)
IGamma hydroxybutyric acid (2010)
IMethaqualone (2565)
IAlpha-Ethyltryptamine (7249)
ILysergic acid diethylamide (7315)
ITetrahydrocannabinols (7370)
IMescaline (7381)
I3,4,5-Trimethoxyamphetamine (7390)
I4-Bromo-2,5-dimethoxyamphetaime (7391)
I4-Bromo-2,5-dimethoxyphenethylamine (7392)
I4-Methyl-2,5-dimethoxyamphetamine (7395)
I2,5-Dimethoxyamphetamine (7396)
I2,5-Dimethoxy-4-ethylamphetamine (7399)
I3,4-Methylenedioxyamphetamine (7400)
I5-Methoxy-3,4-methylenedioxyamphetamine (7401)
IN-Hydroxy-3,4-methylenedioxyamphetamine (7402)
I3,4-Methylenedioxy-N-ethylamphetamine (7404)
I3,4-Methylenedioxymethamphetamine (7405)
I4-Methoxyamphetamine (7411)
IBufotenine (7433)
IDiethyltryptamine (7434)
IDimethyltryptamine (7435)
IPsilocybin (7437)
IPsilocyn (7438)
IAcetyldihydrocodeine (9051)
IBenzylmorphine (9052)
ICodeine-N-oxide (9053)
IDihydromorphine (9145)
IHeroin (9200)
IMorphine-N-oxide (9307)
INormorphine (9313)
IPholcodine (9314)
IAcetylmethadol (9601)
IAllyprodine (9602)
IAlphacetylmethadol except Levo-Alphacetylmethadol (9603)
IAlphameprodine (9604)
IAlphamethadol (9605)
IBetacetylmethadol (9607)
IBetameprodine (9608)
IBetamethadol (9609)
IBetaprodine (9611)
IHydromorphinol (9627)
INoracymethadol (9633)
INorlevorphanol (9634)
INormethadone (9635)
ITrimeperidine (9646)
IPara-Fluorofentanyl (9812)
I3-Methylfentanyl (9813)
IAlpha-methylfentanyl (9814)
IAcetyl-alpha-methylfentanyl (9815)
IBeta-hydroxyfentanyl (9830)
IBeta-hydroxy-3-methylfentanyl (9831)
I( print page 10321)Alpha-Methylthiofentanyl (9832)
I3-Methylthiofentanyl (9833)
IThiofentanyl (9835)
IAmphetamine (1100)
IIMethamphetamine (1105)
IIPhenmetrazine (1631)
IIMethylphenidate (1724)
IIAmobarbital (2125)
IIPentobarbital (2270)
IISecobarbital (2315)
IIGlutethimide (2550)
IINabilone (7379)
II1-Phenylcyclohexylamine (7460)
IIPhencyclidine (7471)
II1-Piperidinocyclohexanecarbonitrile (8603)
IIAlphaprodine (9010)
IICocaine (9041)
IICodeine (9050)
IIDihydrocodeine (9120)
IIOxycodone (9143)
IIHydromorphone (9150)
IIDiphenoxylate (9170)
IIBenzoylecgonine (9180)
IIEthylmorphine (9190)
IIHydrocodone (9193)
IILevomethorphan (9210)
IILevorphanol (9220)
IIIsomethadone (9226)
IIMeperidine (9230)
IIMethadone (9250)
IIMethadone-intermediate (9254)
IIMorphine (9300)
IIThebaine (9333)
IILevo-alphacetylmethadol (9648)
IIOxymorphone (9652)
IINoroxymorphone (9668)
IIAlfentanil (9737)
IISufentanil (9740)
IIFentanyl (9801)
II
 The firm plans to manufacture small quantities of the listed controlled substances to make deuterated and non-deuterated drug reference standards which will be distributed to analytical and forensic laboratories for drug testing programs. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration. Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA 
                    **Federal Register**
                     Representative (CCR), and must be filed no later than April 16, 2001. Dated: January 25, 2001. Laura M. Nagel, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.


[FR Doc. 01-3752  Filed 2-13-01; 8:45 am] BILLING CODE 4410-09-M